EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adicet Bio's enterprise value is $27.58 Mil.
Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-136.54 Mil. Therefore, Adicet Bio's EV-to-EBITDA for today is -0.20.
The historical rank and industry rank for Adicet Bio's EV-to-EBITDA or its related term are showing as below:
ACET'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.3 Med: -1.82 Max: 2.77
Current: -0.21
During the past 6 years, the highest EV-to-EBITDA of Adicet Bio was 2.77. The lowest was -20.30. And the median was -1.82.
ACET's EV-to-EBITDA is ranked worse than 100% of 469
companies
in the Biotechnology industry
Industry Median: 9.16
vs ACET: -0.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Adicet Bio's stock price is $1.95.
Adicet Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.310. Therefore, Adicet Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Adicet Bio EV-to-EBITDA Historical Data
The historical data trend for Adicet Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Adicet Bio Annual Data
Trend
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-
-5.34
-7.26
-2.20
0.42
Adicet Bio Quarterly Data
Dec18
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-2.20
-0.39
0.71
0.74
0.42
Competitive Comparison
For the Biotechnology subindustry, Adicet Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Adicet Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adicet Bio's EV-to-EBITDA falls into.
Adicet Bio EV-to-EBITDA Calculation
Adicet Bio's EV-to-EBITDA for today is calculated as:
Adicet Bio's current Enterprise Value is $27.58 Mil.
Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-136.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (NAS:ACET) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Adicet Bio's share price for today is $1.95.
Adicet Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Adicet Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACET has been successfully added to your 